Klinikum Klagenfurt am Wörthersee
- Address
- Feschnigstraße 11, 9020 Klagenfurt, Austria
Neoplasms and Male Urogenital Diseases
At Klinikum Klagenfurt am Wörthersee, clinical research in neoplasms focuses on early breast cancer and prostate carcinoma, with studies aimed at improving long-term cancer control and easing treatment-related complications.
- Testing a new endocrine-based approach to help prevent recurrence in ER+/HER2- early breast cancer
- Evaluating a rectal therapy to relieve acute radiation proctitis symptoms in men treated for prostate cancer
These studies reflect a strong interest in both cancer recurrence prevention and supportive care for patients experiencing side effects from radiation treatment.
Nervous System Diseases
The site is also active in nervous system diseases, especially migraine, where trials are examining better ways to prevent attacks and provide faster relief during episodes.
- Assessing a preventive treatment for adults with frequent migraine attacks and limited response to prior therapies
- Comparing an acute treatment option with placebo to improve migraine headache pain relief
These studies aim to improve both day-to-day migraine control and treatment options for people who do not respond well to standard medications.
Cardiovascular Diseases
Research in cardiovascular diseases at the department includes work on pulmonary hypertension linked with heart failure with preserved ejection fraction, a complex condition that can severely limit exercise capacity and quality of life.
- Evaluating whether a new treatment can improve walking distance and physical function in PH-HFpEF
- Assessing the safety and tolerability of a therapy intended to support patients with advanced cardiopulmonary symptoms
This line of research is centered on improving symptoms, exercise tolerance, and treatment safety in a challenging heart-lung disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Klagenfurt am Wörthersee
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF | Tenax Therapeutics Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rimegepant | 2 | Unknown | 2023-03-14 | 2023-03-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.